Literature DB >> 15246263

Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression.

Jeffrey Vieira1, Patricia M O'Hearn.   

Abstract

A hallmark of all herpesvirus is the ability to exist in either a latent, or lytic, state of replication, enabling the lifelong infection of its host. Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) can efficiently establish a latent infection in a variety of cell types in vitro, making it a valuable model for the study of latency and reactivation. To facilitate the identification of KSHV lytic replication, and allow subsequent experiments with live cells, a recombinant virus, rKSHV.219, was constructed using JSC-1 cells that expresses the red fluorescent protein (RFP) from the KSHV lytic PAN promoter, the green fluorescent protein (GFP) from the EF-1alpha promoter, and with the gene for puromycin resistance as a selectable marker. rKSHV.219 from JSC-1 cells was used to infect Vero cells for purification of the recombinant virus. Vero cells were also used for the production of rKSHV.219 at levels of 10(5)-10(6) infectious units (IU) of virus per milliliter using a combination of KSHV/RTA expressed from a baculovirus vector, BacK50, and butyrate. Virus produced from Vero cells was used to infect human fibroblasts (HF), 293, DU145, T24, HaCaT, and HEp-2 cells, and in all cells except 293 cells, only a latent infection was established with GFP expression, but no RFP expression. In 293 cells, 10-15% of cells showed lytic gene expression. Both primary and immortalized microvascular endothelial cells (MVEC) were also infected with rKSHV.219, and reduced spontaneous lytic replication was found in immortalized cells. In all cells used in this study, rKSHV.219 efficiently established latent infections from which the virus could be reactivated to productive lytic replication. This work also demonstrated strong synergy between KSHV/RTA and butyrate for the activation of KSHV lytic replication and the production of infectious virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246263     DOI: 10.1016/j.virol.2004.03.049

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  219 in total

1.  The lytic transcriptome of Kaposi's sarcoma-associated herpesvirus reveals extensive transcription of noncoding regions, including regions antisense to important genes.

Authors:  Sanjay Chandriani; Yiyang Xu; Don Ganem
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen.

Authors:  Mel Campbell; Pei-Ching Chang; Steve Huerta; Chie Izumiya; Ryan Davis; Clifford G Tepper; Kevin Y Kim; Bogdan Shevchenko; Don-Hong Wang; Jae U Jung; Paul A Luciw; Hsing-Jien Kung; Yoshihiro Izumiya
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

3.  Multiple defects, including premature apoptosis, prevent Kaposi's sarcoma-associated herpesvirus replication in murine cells.

Authors:  Kathryn Austgen; Scott A Oakes; Don Ganem
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

4.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

5.  The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.

Authors:  Alexander S Hahn; Johanna K Kaufmann; Effi Wies; Elisabeth Naschberger; Julia Panteleev-Ivlev; Katharina Schmidt; Angela Holzer; Martin Schmidt; Jin Chen; Simone König; Armin Ensser; Jinjong Myoung; Norbert H Brockmeyer; Michael Stürzl; Bernhard Fleckenstein; Frank Neipel
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

6.  Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  John A West; Sean M Gregory; Vijay Sivaraman; Lishan Su; Blossom Damania
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Inhibition of RIG-I-mediated signaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64.

Authors:  Kyung-Soo Inn; Sun-Hwa Lee; Jessica Y Rathbun; Lai-Yee Wong; Zsolt Toth; Keigo Machida; Jing-Hsiung James Ou; Jae U Jung
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

8.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

9.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.